Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

BACKGROUND: Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-related adverse events (irAEs) including colitis, dermatitis, and pneumonitis a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiuan, Eileen, Beckermann, Kathryn E., Ozgun, Alpaslan, Kelly, Ciara, McKean, Meredith, McQuade, Jennifer, Thompson, Mary Ann, Puzanov, Igor, Greer, John P., Rapisuwon, Suthee, Postow, Michael, Davies, Michael A., Eroglu, Zeynep, Johnson, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319013/
https://www.ncbi.nlm.nih.gov/pubmed/28239462
http://dx.doi.org/10.1186/s40425-017-0210-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319013/
https://www.ncbi.nlm.nih.gov/pubmed/28239462
http://dx.doi.org/10.1186/s40425-017-0210-0

Ejemplares similares